SCHEMBL3206387

SCHEMBL3206387

c1ccc(COC2CN3CCC2CC3)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 3/20 0.58
CHRM2 P08172 9/20 0.51
CHRM1 P11229 9/20 0.51
CHRM3 P20309 9/20 0.51
CTSV O60911 1/20 0.49
CTSL P07711 1/20 0.49
CTSB P07858 1/20 0.49
CTSS P25774 1/20 0.49
CTSK P43235 1/20 0.49
CTSC P53634 1/20 0.49
CTSF Q9UBX1 1/20 0.49
CYP2D6 P10635 1/20 0.49
BCHE P06276 1/20 0.49
ACHE P22303 1/20 0.49
CHRM5 P08912 6/20 0.48
CHRM4 P08173 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3218557 1.00 CHRNA7 (0.58) CHRNA7CHRM2CHRM1CHRM3CTSV
SCHEMBL3222951 1.00 CHRNA7 (0.58) CHRNA7CHRM2CHRM1CHRM3CTSV
Hydrochloric Acid SCHEMBL8988206 0.93 CHRNA7 (0.52) CHRNA7CHRM2CHRM1CHRM3CTSV
SCHEMBL4197310 0.91 CHRNA7 (0.53) CHRNA7CHRM2CHRM1CHRM3
SCHEMBL9707154 0.87 CHRNA7 (0.50) CHRNA7CHRM2CHRM1CHRM3CYP2D6
Hydrochloric Acid SCHEMBL8988244 0.86 CHRNA7 (0.49) CHRNA7CHRM2CHRM1CHRM3CYP2D6
Hydrochloric Acid SCHEMBL8988338 0.86 CHRNA7 (0.49) CHRNA7CHRM2CHRM1CHRM3CYP2D6
Hydrochloric Acid SCHEMBL8988432 0.84 CHRNA7 (0.50) CHRNA7CHRM2CHRM1CHRM3CYP2D6
SCHEMBL3219330 0.84 MEN1 (0.51) CHRNA7CHRM2CHRM1CHRM3CHRM5
SCHEMBL3210416 0.84 GLA (0.54) CHRNA7CHRM2CHRM1CHRM3CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056565-A1 Heterocyclic Derivatives as M3 Muscarinic Receptors ARGENTA DISCOVERY LIMITED (GB) 2010-03-04 US disclosed
EP-2121688-A1 HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS Argenta Discovery Ltd (GB) 2009-11-25 EP disclosed
WO-2008099186-A1 HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS ARGENTA DISCOVERY LIMITED (GB) 2008-08-21 WO disclosed
US-4675326-A MONO AND BIS-PYRIDINIUM OXIMES FOR ORGANOPHOSPHOROUS AND CARB AMATE POISONING STATE OF ISRAEL, PRIME MINISTERS OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH 1987-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056565-A1 Heterocyclic Derivatives as M3 Muscarinic Receptors CHRM2, CHRM3, CHRM1 CHRNA7 13/4885CHRM2 1/4885CHRM1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.